Reyad Ayman Antoun, Mishriky Raafat
School of Pharmacy, University of Wolverhampton, WV1 1LY, Wolverhampton, UK,
Psychiatr Danub. 2019 Jun;31(2):157-161. doi: 10.24869/psyd.2019.157.
Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks. Asenapine is a new second-generation antipsychotic, available as a sublingual tablet, approved in Europe for the treatment of moderate-to-severe manic episodes in adults, and in US for manic or mixed episodes of bipolar I disorder in adults and adolescents. In this review, we searched the available literature to appreciate the role of asenapine in the management of psychiatric conditions such as bipolar disorders and schizophrenia and describe its mechanism of action, efficacy and tolerability. Asenapine has demonstrated efficacy in the management of bipolar disorders and schizophrenia, while a possible role in the management of borderline personality disorder and agitation needs further research. Asenapine has favourable side effects profile and combining with other pharmacological treatment in post-traumatic stress disorder has shown promising results. Asenapine fulfils important requirements of efficacy and tolerability as an anti-psychotic. These findings should support psychiatrists and pharmacists in the care of their patients while on asenapine.
精神分裂症和双相情感障碍是具有重大健康风险的严重精神疾病。阿塞那平是一种新型第二代抗精神病药物，有舌下片剂型，在欧洲被批准用于治疗成人中度至重度躁狂发作，在美国被批准用于治疗成人及青少年双相I型障碍的躁狂或混合发作。在本综述中，我们检索了现有文献，以了解阿塞那平在双相情感障碍和精神分裂症等精神疾病管理中的作用，并描述其作用机制、疗效和耐受性。阿塞那平已在双相情感障碍和精神分裂症的管理中显示出疗效，而其在边缘性人格障碍和激越管理中的可能作用需要进一步研究。阿塞那平具有良好的副作用谱，并且与创伤后应激障碍的其他药物治疗联合使用已显示出有前景的结果。阿塞那平作为一种抗精神病药物满足了疗效和耐受性的重要要求。这些发现应有助于精神科医生和药剂师在患者使用阿塞那平治疗时对其进行护理。
